NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APTX shares have increased by 87.7% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aptinyx.

Aptinyx Inc (NASDAQ:APTX) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The company earned $0.82 million during the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%. View Aptinyx's earnings history.

6 Wall Street analysts have issued 12-month price objectives for Aptinyx's stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Aptinyx's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View analysts' price targets for Aptinyx.

News stories about APTX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Aptinyx.

Aptinyx saw a increase in short interest in June. As of June 30th, there was short interest totaling 659,300 shares, an increase of 115.4% from the June 15th total of 306,100 shares. Based on an average daily volume of 292,200 shares, the short-interest ratio is currently 2.3 days. Approximately 3.0% of the shares of the stock are sold short. View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include ImmunoGen (IMGN), Kura Oncology (KURA), Cara Therapeutics (CARA), G1 Therapeutics (GTHX), Assembly Biosciences (ASMB), Morphic (MORF), Endo International (ENDP), Kadmon (KDMN), Stoke Therapeutics (STOK), Omeros (OMER), Legend Biotech (AMTI), Applied Therapeutics (APLT), Frequency Therapeutics (FREQ), Passage Bio (ORIC) and Homology Medicines (FIXX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $4.56.

Aptinyx has a market capitalization of $208.21 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]